Lilly, Merck double down on peptide-targeted drug delivery, betting billions in biobucks on PeptiDream pacts

Eli Lilly and Merck & Co. have identified PeptiDream’s peptides as a way to deliver therapeutic payloads to targets, leading them both to lay down more than $1 billion in milestones to work with the biotech.